



BioLight Life Sciences Ltd.

September 21, 2025

To: Israel Securities Authority www.isa.gov.il

To: Tel-Aviv Stock Exchange Ltd. www.tase.co.il

Re: Immediate Report Regarding the Results of a Public Offering According to a Shelf Offering Report Dated September 17, 2025

In accordance with Section 30 of the Securities Law, 1968, and the Securities Regulations (Notice on Results of an Offer in a Prospectus), 1969, BioLight Life Sciences Ltd. ("**the Company**") hereby announces the results of the offering under the Company's Shelf Offering Report dated September 17, 2025 ("**the Shelf Offering Report**"), which was published according to the Company's shelf prospectus.

1. As part of the Shelf Offering Report, the Company offered securities to the public in a uniform offering with a quantity range, as detailed in Section 1 of the Shelf Offering Report.
2. The securities were offered to the public by way of a tender for the price per unit ("**the Tender**"), which shall not be less than NIS 460 ("**the Minimum Unit Price**"), with the composition and price of each unit as follows:

Unit Composition	Price
100 ordinary shares at a price of NIS 4.6 per share	NIS 460
100 warrants (Series 9)	For no consideration
100 warrants (Series 10)	For no consideration
Total Minimum Unit Price:	NIS 460

3. The aforementioned securities offering was not underwritten.
4. The public offering tender took place on September 18, 2025. The period for submitting orders to purchase units offered to the public, as detailed above in this report, closed on the same day at 5:30 PM.
5. **Below are the tender results:**
 - 5.1. In the public offering tender, 58 orders were received for the purchase of 43,581 units, which include 4,358,100 ordinary shares of the Company, 4,358,100 Series 9 warrants, and 4,358,100 Series 10 warrants.
 - 5.2. The unit price determined in the public offering tender is NIS 460 ("**the Uniform Unit Price**").
 - 5.3. In accordance with the terms of the Offering Report, a total of 43,581 units were allocated in the tender, as follows:

- 5.3.1. 18 orders from the public for the purchase of 3,998 units, in which a unit price higher than the Uniform Unit Price set in the tender was quoted, were fully met.
- 5.3.2. 40 orders from the public for the purchase of 39,583 units, in which a unit price equal to the Uniform Unit Price set in the tender was quoted, were fully met.
- 6. The immediate (gross) proceeds to be received by the Company for the requests that were met as detailed above amount to approximately NIS 20 million.
- 7. The expected future (gross) proceeds for the Company are as follows: Assuming that all Series 9 warrants, with an exercise price of NIS 6 for each warrant, and all Series 10 warrants, with an exercise price of NIS 7.5 for each warrant, that were offered and will be allocated according to the Shelf Offering Report are exercised into ordinary shares of the Company by their respective last exercise dates, the proceeds from the exercise of the said warrants will total to approximately NIS 59 million.

The Company thanks the investors for its response to the offer under the Shelf Offering Report.

Sincerely,

Biolight Life Sciences Ltd.

NON-BINDING TRANSLATION

The above-mentioned immediate report is a free translation of the Company's immediate report in Hebrew published on the TASE on September 21, 2025. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.